Aggregate Safety Assessment Planning for the Drug Development Life-Cycle

Area of Science:

• Pharmacovigilance and Drug Safety
• Clinical Trial Analysis
• Regulatory Science

Background:

• The Program Safety Analysis Plan (PSAP) was previously introduced for integrated product safety data analysis.
• The evolving regulatory landscape necessitates adaptive safety assessment strategies.
• The Drug Information Association-American Statistical Association (DIA-ASA) Interdisciplinary Safety Evaluation working group identified a need for a more dynamic approach.

Purpose of the Study:

• To propose the Aggregate Safety Assessment Plan (ASAP) process, an evolution of the PSAP.
• To promote interdisciplinary and systematic safety planning across a product's lifecycle.
• To standardize aggregate safety evaluations while tailoring analyses to specific drug development programs.

Main Methods:

• The ASAP process is designed to be modular and flexible, adapting to program complexity, development phase, and sponsor processes.
• It involves ongoing data review and characterization of the emerging product safety profile.
• Key objectives include aligning on safety topics, identifying knowledge gaps, planning aggregate evaluations, and preparing safety communications.

Main Results:

• Implementation of the ASAP process facilitates early safety signal detection.
• It improves the characterization of product risks and potential adverse events.
• The ASAP process harmonizes safety messaging and informs critical program decision-making.

Conclusions:

• The ASAP process offers a structured yet adaptable approach to aggregate safety assessment in drug development.
• It supports proactive safety planning, continuous data review, and informed decision-making.
• This framework is crucial for navigating complex regulatory environments and ensuring robust product safety evaluation.